The startup has developed a mucoadhesive drug delivery platform that enhances the efficacy of ocular treatments for conditions such as glaucoma and dry eye. By focusing on targeted eye drops, the platform ensures prolonged drug retention on the mucosal surface, improving therapeutic outcomes for patients experiencing vision loss.
Funding
$430K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current eye drop formulations for conditions like glaucoma and dry eye are often inefficient, with a large percentage of the drug being lost after the first blink, leading to low bioavailability and the need for frequent administration. This frequent dosing can cause discomfort, irritation, and poor patient compliance, reducing the effectiveness of the treatment.
Solution
20|20 OptimEyes Technologies is developing a novel drug delivery platform based on mucoadhesive micelle nanoparticles (MNPs) to improve the efficacy and patient experience of ocular treatments. Their patented technology allows for greater drug loading, enhanced retention on the ocular surface, sustained release, and decreased ocular irritation. By encapsulating drugs within the core of the MNPs and utilizing a binding moiety to adhere to the eye, the platform aims to reduce the required dosing frequency from twice daily to once or twice weekly. In-vivo studies have demonstrated that their MNPs achieve significantly higher drug concentrations on the eye compared to standard formulations, with equivalent or superior efficacy in preclinical models of dry eye and glaucoma.
Target Audience
The primary target audience includes patients suffering from glaucoma and dry eye disease, as well as ophthalmologists and optometrists seeking more effective and convenient treatment options.
Features
- Patented mucoadhesive micelle nanoparticle (MNP) technology for enhanced drug delivery
- Increased drug loading within the core of the micelle
- Binding moiety for prolonged residence time on the ocular surface
- Sustained drug release for greater bioavailability
- Aqueous formulation to decrease ocular irritation
- Demonstrated 6x greater drug quantities on the eye after a single dose compared to standard MNPs
- Equivalent efficacy to Restasis in a dry eye rat model with less frequent dosing
- Granted patents in the United States, Europe, and Japan, with a pending Canadian application